HLA-DQ8: Key MHC L MoleculeIn Autoimmune Diseases (P36339)

Target Name: HLA Class II Histocompatibility Antigen DQ8

NCBI ID: P36339

HLA Class II Histocompatibility Antigen DQ8

Other Name(s): HLA-DQ8 | MHC DQ beta | Major Histocompatibility Complex, Class II, DQ8 | MHC class II DQ8

HLA-DQ8: Key MHC L MoleculeIn Autoimmune Diseases

HLA (Human Leukocyte Antigen) is a family of molecules that are involved in the immune response. HLA molecules are present in the immune system throughout the body, and they play a crucial role in the recognition of self and non-self antigens. HLA-DQ8 is one of the most well-studied HLA molecules, and it is known as the histocompatibility antigen DQ8.

HLA-DQ8 is a 26-kDa protein that is expressed in most tissues of the body. It is a key component of the major histocompatibility complex (MHC), which is a complex of antigens that are recognized by the immune system. HLA-DQ8 is one of the six class II molecules that are expressed in the MHC.

DQ8 molecules are involved in the presentation of antigens to CD4+ T cells. These molecules are processed and loaded onto the major histocompatibility complex (MHC) molecules. CD4+ T cells are the main immune cells that recognize and respond to antigens. The MHC molecules are loaded with antigens, and they are recognized by CD4+ T cells by their major histocompatibility complex (MHC) class II molecules.

HLA-DQ8 is a critical molecule for the immune response, and it is involved in the recognition of self and non-self antigens. It is one of the most well-studied HLA molecules, and it is known for its role in the development of autoimmune diseases.

DQ8 molecules are involved in the presentation of antigens to CD4+ T cells. These molecules are processed and loaded onto the major histocompatibility complex (MHC) molecules. CD4+ T cells are the main immune cells that recognize and respond to antigens. The MHC molecules are loaded with antigens, and they are recognized by CD4+ T cells by their major histocompatibility complex (MHC) class II molecules.

HLA-DQ8 is a key molecule for the immune response, and it is involved in the recognition of self and non-self antigens. It is one of the most well-studied HLA molecules, and it is known for its role in the development of autoimmune diseases.

DQ8 molecules are processed and loaded onto the MHC class II molecules through a process called antigen cross-presentation. This process involves the presentation of antigens from exogenous sources, such as viruses or bacteria, to the immune system by dendritic cells. DQ8 molecules are processed in the cytoplasm and then loaded onto the MHC class II molecules through a process called antigen cross-presentation.

DQ8 molecules are involved in the presentation of antigens to CD4+ T cells. These molecules are processed and loaded onto the major histocompatibility complex (MHC) molecules. CD4+ T cells are the main immune cells that recognize and respond to antigens. The MHC molecules are loaded with antigens, and they are recognized by CD4+ T cells by their major histocompatibility complex (MHC) class II molecules.

HLA-DQ8 is a critical molecule for the immune response, and it is involved in the recognition of self and non-self antigens. It is one of the most well-studied HLA molecules, and it is known for its role in the development of autoimmune diseases.

Conclusion

HLA-DQ8 is a critical molecule for the immune response, and it is involved in the recognition of self and non-self antigens. It is one of the most well-studied HLA molecules, and it is known for its role in the development of autoimmune diseases. Further research is needed to fully understand the role of HLA-DQ8 in the immune response and its potential as a drug target or biomarker.

Protein Name: HLA Class II Histocompatibility Antigen DQ8

The "HLA Class II Histocompatibility Antigen DQ8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA Class II Histocompatibility Antigen DQ8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets